Aethlon Medical Receives Full Ethics Approval for Hemopurifier Clinical Trial in Cancer Patients With Solid Tumors Unresponsive to Anti-PD-1 Therapy
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical has received full ethics approval to conduct a clinical trial for its Hemopurifier in cancer patients with solid tumors unresponsive to anti-PD-1 therapy. This approval marks a significant milestone for the company in advancing its medical technology.
June 18, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aethlon Medical has received full ethics approval to conduct a clinical trial for its Hemopurifier in cancer patients with solid tumors unresponsive to anti-PD-1 therapy. This approval is a significant milestone for the company.
The full ethics approval for the Hemopurifier clinical trial is a critical step forward for Aethlon Medical. This development could lead to positive investor sentiment and potential stock price appreciation as it signifies progress in their clinical research and potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100